Tonix depression drug trial ended after endpoint miss

 The study did not achieve statistical significance on the primary endpoint

Tonix is discontinuing development of TNX-601 ER based on the efficacy results of this study

Tonix expects topline data results in December 2023 for its Phase 2 study of TNX-1900 in chronic migraine and Phase 3 study of TNX-102 SL in fibromyalgia

https://www.globenewswire.com/news-release/2023/10/31/2770686/28908/en/Tonix-Pharmaceuticals-Announces-Topline-Results-from-Phase-2-Proof-of-Concept-Study-of-TNX-601-ER-for-the-Treatment-of-Major-Depressive-Disorder.html